This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
FRAME-001 is a stable personalized vaccine formulation for advanced NSCLC, stable for up to 32 weeks.
Why it matters
This research could lead to more effective personalized therapies for lung cancer, potentially improving patient outcomes. It also sets a precedent for developing similar vaccines for other cancers.
How the study worked
The study involved synthesizing neoantigen peptides and formulating them into a vaccine under good manufacturing practices, followed by stability testing.
What this study cannot tell us
The study primarily focuses on formulation and stability, with clinical efficacy yet to be established in trials.
Read the original research
Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer.
Pharmaceutics, 14(7)
Citation
Oosting, Linette T; Franke, Katka; Martin, Michael V; Kloosterman, Wigard P; Jamieson, Jennifer A; Glenn, Laura A; de Jager, Miranda W; van Zanten, Jacoba; Allersma, Derk P; Gareb, Bahez. (2022). Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer.. Pharmaceutics, 14(7). https://doi.org/10.3390/pharmaceutics14071515